MS-based technology for simultaneous screening of several enzyme activities related to lysosomal storage disorders from DBS was developed, replacing the old methods and enabling the assay of single enzyme activity. Li et al (1) fi rst developed a direct multiplex assay of lysosomal enzymes for Gaucher, Pompe, Krabbe, Fabry and Niemann-Pick A/B diseases in DBS by fl ow injection analysis (FIA) tandem mass spectrometry. Since then, an expansion of simultaneously diagnosable disorders by MS has been reported. Some countries already include some LSDs in their newborn screening panels, and local or pilot programmes have been launched in others. (2-6).
CONCLUSIONS
It is currently debated whether or not LSD diseases should be included in a general NBS worldwide programme. In 2014, most LDS pilot projects include Pompe disease. In general, NBS for LSD could identify asymptomatic forms; it is not able to discriminate between treatable and untreatable forms, surely it cannot suggest if and when to start therapy. However, even if long-term clinical studies are not available, it seems that Pompe disease meets the criteria for inclusion in NBS, including basal availability of a simple test, a combination therapy that modifi es the natural course of the disease, and early diagnosis that allows for genetic counsel ling and prenatal diagnosis in families with an affected baby.
